Phase 2 CD20 Clinical Trials

7 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 17 of 7 trials

Recruiting
Phase 2

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaBurkitt Lymphoma+3 more
New York Medical College25 enrolled1 locationNCT02393157
Recruiting
Phase 2

Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL

Initial MZLUntreated MZLBTKi+1 more
Li Zhiming33 enrolled2 locationsNCT06985472
Recruiting
Phase 2

Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

CD20-positive Acute Lymphoblastic Leukemia
Maria Sklodowska-Curie National Research Institute of Oncology124 enrolled19 locationsNCT04920968
Recruiting
Phase 1Phase 2

Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

CD20-positive Non-Hodgkin Lymphoma
Guangzhou Excelmab Inc.415 enrolled4 locationsNCT06021678
Recruiting
Phase 2

Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)

Resolved Hepatitis BCD20 Positive B-cell Lymphoma
Sun Yat-sen University84 enrolled1 locationNCT05453435
Completed
Phase 2

A multi-centre phase II trial of early treatment intensification with R-ICE (rituximab – ifosfamide, carboplatin, etoposide) chemotherapy followed by BEAM ( BCNU(BCNU is Carmustine), etoposide, ara-C (ara-C is Cytarabine), melphalan) high dose chemotherapy and autologous stem cell transplantation for patients with poor prognosis diffuse large B-cell lymphoma

Patients with CD20+ diffuse large B cell lymphoma (DLBCL) with low intermediate, high intermediate, or high risk disease or low risk disease with bulky tumour (> 7.5 cm) who are considered fit and eligible for high dose chemotherapy (HDCT) with Z-BEAM ( Zevalin - BEAM ( BCNU(BCNU is Carmustine), etoposide, ara-C (ara-C is Cytarabine), melphalan) and autologous stem cell transplantation (ASCT).
Australasian Leukaemia and Lymphoma Group (ALLG)162 enrolled1 locationACTRN12609001077257
Completed
Phase 2

A Pilot Study to Evaluate the Safety and Efficacy of Rituximab in Combination with Out-Patient Based Vinorelbine, Gemcitabine and Pegfilgrastim (VGF)/Pegfilgrastim, Gemcitabine, Ifosfamide and Vinorelbine (F-GIV) Salvage Therapies in the treatment of Relapsed/Refractory CD20+ Lymphomas.

Relapsed and refractory CD20+ lymphoma
Associate Professor Andrew Spencer12 enrolled1 locationACTRN12606000386538